PDCD1 and neoplasm: Aiming to boost the function of the immune system and elicit an anti-tumor response via T-cell activation, a number of agents targeting immune checkpoint inhibitors of the PD-1/PDL-1 pathway are already approved by food and drug administration (FDA) for different cancer types [198,199].